Long-term follow-up of patients with nodular lymphocyte predominant Hodgkin lymphoma: A report from the Spanish Lymphoma Oncology Group.
Hodgkin lymphoma
long-term follow-up
lymphocyte predominant
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
revised:
21
11
2020
received:
17
06
2020
accepted:
21
12
2020
pubmed:
3
2
2021
medline:
13
10
2021
entrez:
2
2
2021
Statut:
ppublish
Résumé
Nodular lymphocytic predominance Hodgkin lymphoma (NLPHL) is a very uncommon subtype of Hodgkin lymphoma (HL), representing approximately 5% of all HL cases, with an incidence of 0.3/100,000 cases per year and with unique characteristics which distinguish it from classic Hodgkin lymphoma. Given its low frequency, there is a lack of prospective randomized studies to inform practice, the accumulated experience of academic groups being the main source of relevant information for the management of these patients. Eighty-five patients recruited by the Spanish Lymphoma Group (GOTEL) from 12 different hospitals were retrospectively analyzed to describe their sociodemographic and clinical characteristics. The median follow-up was 16 years, with a 10-year overall survive of 92.9% and 81.2% at 20 years. Five patients developed a second malignancy. No transformation to a more aggressive lymphoma was detected. A total of 31% tumor relapses was found: 77% in a single location; most of them at a supra-diaphragmatic level. Patients received different first-line treatments, and progression was observed in 3/4 (75%) of the patients who did not receive any type of treatment, 6/23 (26%) who received both chemotherapy (CH) and radiotherapy (RT), 12/43 (27%) who received RT and 7/15 (47%) that received only CH treatment. The mean time to relapse was 3 years and 47% presented relapses beyond 5 years (higher probability in stage IV p < 0.001). This is one of the longest follow-up series of NLPHL published, confirming its excellent prognosis, and that treatments may be adapted to reduce toxicity. Causes of death in these patients are varied, and the minority due to a primary malignancy relapses.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
506-512Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Shanbhag S, Ambinder R. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018;68(2):116-132.
Spinner MA, Varma G, Advani RH. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol. 2019;184(1):17-29.
Wilson MR, Bagguley T, Smith A, et al. Frontline management of nodular lymphocyte predominant Hodgkin lymphoma- a retrospective UK multicentre study. Br J Haematol. 2019;186(6):e214-e217.
Savage KJ, Mottok A, Fanale M. Nodular lymphocyte-predominant Hodgkin lymphoma. Semin Hematol. 2016;53(3):190-202.
Eichenauer DA, Engert A. Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management. Haematology Am Soc Hematol Educ Program. 2017;8(1):324-328.
Ekstrand BC, Lucas JB, Horwithz SM, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood. 2003;102:4285.
Nogová L, Reineke T, Brillant C, et al. Lymphocyte-predominant and classical Hodgkin´s lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol. 2008;26(3):434-439.
Provencio M, España P, Millán I, et al. Prognostic factors in Hodgkin's disease. Leuk Lymphoma. 2004;45(6):1133-1139.
Al-Mansour M, Connors JM, Gascoyne RD, et al. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. J Clin Oncol. 2010;28(5):793-799.
Biasoli I, Stamatoullas A, Meignin V, et al. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the adult lymphoma study group. Cancer. 2010;116(3):631-639.
Kenderian SS, Habermann TM, Macon WR, et al. Large B-cell transformation in nodular lymphocyte predominant Hodgkin lymphoma: forty-year experience from a single institution. Blood. 2016;127(16):1960-1966.
Advani RH, Horning SJ, Hoppe RT, et al. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol. 2014;32(9):912-918.
Binkley MS, Rauf MS, Milgrom SA, et al. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood. 2020;135(26):2365-2374.
Méndez M, Torrente M, Sánchez-Beato M, et al. Transformed follicular lymphoma in the rituximab era: a report from the Spanish Lymphoma Oncology Group. Hematol Oncol. 2019;37(2):143-150.
Borchmann S, Joffe E, Moskowitz CH, et al. Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2019;133(20):2121-2129.
Nogová L, Reineke T, Josting A, et al. Lymphocyte-predominant and classical Hodgkin´s lymphoma comparison of outcomes. Eur J Haematol Suppl. 2005(66):106-110.
Wirth A, Yuen K, Barton M, et al. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer. 2005;104(6):1221-1229.
Chen RC, Chin MS, Ng AK, et al. Early-stage, lymphocyte-predominant Hodgkin´s lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol. 2010;28(1):136-141.
Eichenauer DA, Plütschow A, Fuchs M, et al. Long-term course of patients with stage ia nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. J Clin Oncol. 2015;33(26):2857-2862.
Savage KJ, Skinnider B, Al-Mansour M, et al. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood. 2011;118(17):4585-4590.
Shankar A, Hall GW, Gorde-Grosjean S, et al. Treatment outcome after low intensity chemotherapy (CVP) in children and adolescents with early stage nodular lymphocyte predominant Hodgkin´s lymphoma-an Anglo-French Collaborative Report. Eur J Cancer. 2012;48(11):1700-1706.
Mauz-Körholz C, Gorde-Grosjean S, Hasenclever D, et al. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer. 2007;110(1):179-185.
Appel BE, Chen L, Buxton AB, et al. Minimal treatment of low-risk, pediatric lymphocyte-predominant Hodgkin lymphoma: a report from the Children´s Oncology Group. J Clin Oncol. 2016;34(20):2372-2379.
Eichenauer DA, Plütschow A, Fuchs M, et al. Long-term follow-up of patients with nodular lymphocyte-predominant Hodgkin lymphoma treated in the HD7 to HD15 trials: a report from the German Hodgkin Study Group. J Clin Oncol. 2020;38(7):698-705.